USA flag logo/image

An Official Website of the United States Government

Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43DE022986
Solicitation Year:
2013
Solicitation Topic Code:
NIDCR
Solicitation Number:
PA12-088
Small Business Information
ADP SILVER DENTAL ARREST, LLC
442 SW UMATILLA AVE, STE 200 REDMOND, OR 97756-7039
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis
Agency: HHS
Contract: 1R43DE022986-01A1
Award Amount: $117,198.00
 

Abstract:

DESCRIPTION (provided by applicant): Topical fluorides have been the mainstay in the prevention of dental caries for decades. However, topical fluoride alone is not enough to thwart tooth decay in high-risk populations. The purpose of this Phase I application is to determine the technical and scientific feasibility of using a combination povidone-iodine (PVP-I)-5% sodium fluoride (NaF) varnish as a potential commercial product to prevent dental caries. The research will be conducted by the small business firm ADP Silver Dental Arrest, LLC, in collaboration with experienced researchers at the University of Washington Northwest Center to Reduce Oral Health Disparities. The Premier Dental Products Company will prepare the varnish to the specifications of the applicant at no cost to the grant. The Specific Aims of this Phase I SBIR are to: (1) Demonstrate that a new povidone iodine-sodium fluoride varnish has antimicrobial activity and fluoride bioavailability and enamel remineralization ability. (a) Use the in vitro moel developed by Castillo and colleagues to determine the bioavailability of fluoride and iodine release from an experimental povidone-iodine- sodium fluoride varnish; (b) Use an in vitro model of Tanzer and colleagues to assess the additive (indifferent), potentially synergistic, or potentially antagonistic effects of sodium fluoride and povidone-iodine against Streptococcus mutans using the criteria of Eliopoulos and Moellering; (c) Use a slight modification the Featherstone laboratory pH cycling model to test remineralization. (2) Assess the esthetic and organoleptic properties of the new povidone iodine-sodium fluoride varnish. Caries researchers for sometime have suggested strategies that combine an antiseptic with topical fluoride to reduce or eliminate the oral cariogenic bacteria reservoir in addition to topical fluoride which primarily remineralizes teeth enamel. Povidone-iodine is an FDA-approved and widely used bactericidal antiseptic. For the oral flora, iodine has preferential activities against streptococcl species. Moreover, iodine's effectiveness may last as long as six months. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: In this application we propose to: (1) use an in vitro model to determine the bioavailability of fluoride and iodine release from a povidone-iodine-sodium fluoride varnish; (2) use an in vitro model to assess the additive, potentially synergistic, or antagonistic effects of sodium fluoride and povidone-iodine against Streptococcus mutans, the primary pathogens in human dental caries; 3) use a pH cycling model to test remineralization; and 4) assess the organoleptic characteristics of test varnishes.

Principal Investigator:

R. M. Shirtcliff
541-504-3913
mikes@advantagedental.com

Business Contact:

R. M. Shirtcliff
541-504-3913
mikes@advantagedental.com
Small Business Information at Submission:

ADP SILVER DENTAL ARREST, LLC
442 SW UMATILLA AVE, STE 200 REDMOND, OR 97756-7039

EIN/Tax ID: 126026425
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No